OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Chicago - The Biologics License Application for efalizumab (Raptiva) for the treatment of moderate-to-severe plaque psoriasis is set to undergo review by the FDA Dermatologic and Ophthalmic Drugs Advisory Committee this month.